THANK YOU FOR YOUr INTEREST

download the VALUE SUMMARY brochures

pdf REDUCE SPASTICITY AFTER BRAIN INJURY (.pdf)

Intrathecal baclofen (ITB) therapy significantly reduces spasticity, so that your patients are more independent and they need less assistance in transfer.

3.7MB

pdf REDUCE REFRACTORY CANCER PAIN (.pdf)

Targeted drug delivery (TDD) allows your cancer patients to take control of their pain by giving them the ability to manage breakthrough pain 3 times faster compared to conventional medication and receive pain relief with less systemic opioid side effects.

1.1MB

pdf REDUCE SPASTICITY IN CEREBRAL PALSY (CP) (.pdf)

Intrathecal baclofen (ITB) therapy can significantly improve spasticity, pain, and function in children with CP. ITB can also significantly improve both the child’s and parents’ quality of life, due to gains in the child’s independence and their ability to better manage daily activities.

3.0MB

pdf REDUCE SPASTICITY FOR PATIENTS
WITH MULTIPLE SCLEROSIS (MS)
 (.pdf)

Intrathecal baclofen (ITB) therapy significantly reduces disfunction due to spasticity, and significantly improves pain, function and qol, by improving your patient´s sleep, rest and life participation so they can enjoy activities they used to do.

2.9MB

pdf REDUCE SPASTICITY AFTER SPINAL CORD INJURY (.pdf)

Intrathecal baclofen (ITB) therapy significantly decreases the burden of spasticity in terms of muscle tone, tightness and spasms. ITB increases function and QOL, which might lead to improvements in sleep and rest, so that patients may regain their enjoyment of recreation and pastimes.

4.4MB

pdf REDUCE POST-STROKE SPASTICITY (.pdf)

Intrathecal baclofen (ITB) therapy reduces post-stroke spasticity and pain, provides improvements in qol, functional ability, emotional behaviour and social interest, Thus allowing your patients to regain enjoyment in their daily activities.

4.6MB